Micromet Appoints Joseph Lobacki Senior Vice President and Chief Commercial Officer

ROCKVILLE, Md.--(BUSINESS WIRE)-- Micromet, Inc. (NASDAQ: MITI) today announced the appointment of Joseph Lobacki as Senior Vice President and Chief Commercial Officer.

Mr. Lobacki brings to Micromet over 25 years of commercial experience in the biopharmaceutical industry. From 2003 to 2011, Mr. Lobacki served as Senior Vice President and General Manager, Transplant and Oncology at Genzyme and as a member of the company’s senior management team. In this role, he was responsible for directing overall strategy for the company’s global hematology, oncology, and organ transplant business. Under his leadership Genzyme’s transplant/oncology franchise consistently produced double digit percent revenue growth through expansion of product market share, geographical growth, clinical market development and business acquisitions.

"Joe's proven track record in commercializing market leading oncology products makes him a valuable addition to the Micromet management team," said Christian Itin, Ph.D., Micromet’s President and Chief Executive Officer. "His extensive sales, marketing and medical affairs experience will be critical as we look to prepare the marketplace for blinatumomab’s potential launch."

“I am excited to join Micromet during a key growth phase for the company,” said Mr. Lobacki. “I look forward to providing the business direction for the planned launch of blinatumomab in acute lymphoblastic leukemia and helping to maximize the compound’s significant commercial potential across multiple indications.”

Prior to joining Genzyme, Mr. Lobacki served as Vice President, North American Marketing at SangStat Medical Corporation, where he was responsible for all marketing activities for the company’s lead product. Earlier in his career, he served in leadership roles at Cell Pathways and Rhone-Poulenc Rorer. Mr. Lobacki holds a B.S. in Biology from Boston College and a B.S. in Pharmacy from the Massachusetts College of Pharmacy.

About Micromet, Inc.

Micromet is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. The Company is advancing a robust pipeline of novel therapeutics based on its proprietary BiTE® technology. The Company's lead product candidate blinatumomab (MT103) is currently the subject of a European pivotal trial in patients with minimal residual disease positive acute lymphoblastic leukemia. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including Amgen, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, MedImmune, Nycomed and Sanofi.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the development and commercialization of blinatumomab. You are urged to consider statements that include the words "will," "believes," "potential," "plans," "intends," "may," "suggests," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that blinatumomab does not demonstrate safety and/or efficacy in on-going or future clinical trials, delays in development and testing, including the risk that we will not obtain approval to market blinatumomab, and the risks associated with reliance on outside financing to meet capital requirements. These factors and others are more fully discussed in Micromet's Annual Report on Form 10-K, as amended, for the fiscal year ended December 31, 2010, and Micromet's Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2011, filed with the SEC on November 8, 2011 as well as other filings by Micromet with the SEC. Micromet cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Micromet also disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.



CONTACT:

Micromet, Inc.
Jennifer Neiman, Director, Corporate Communications, 240-235-0246
[email protected]

KEYWORDS:   United States  North America  Maryland

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Oncology  Other Health  Research  Other Science  Science

MEDIA:

Suggested Articles

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.

Novavax has brought new CMC head Machielse to head manufacturing; Rexgenero taps Wagener as CMO; EMA nominates Cooke as new director.

The deal grants Sarepta the exclusive right to use Hansa Biopharma’s imlifidase to eliminate neutralizing antibodies in DMD and LGMD patients.